Menu
Back to Journals » Cancer Management and Research » Volume 5
Use and cardiovascular safety of transdermal and other granisetron preparations in cancer management
Received 3 March 2013
Accepted for publication 29 April 2013
Published 29 July 2013 Volume 2013:5 Pages 179—185
DOI https://doi.org/10.2147/CMAR.S34352
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 6
Jay W Mason,1 Thomas E Moon2
1School of Medicine, University of Utah, Salt Lake City, UT, 2Tarizona eHealth Services, Inc, Emeryville, CA, USA
Abstract: 5-HT3 antagonists have been available as oral and intravenous preparations for decades. The availability more recently of transdermal granisetron and the anticipated availability of a subcutaneous granisetron preparation have provided helpful alternatives to patients, and these preparations have been shown to have less potential to prolong QT than other drugs in the class.
Keywords: chemotherapy-induced nausea, vomiting, granisetron, QT prolongation
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.